The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Open accessAbstract
This multicenter, first-in-human study evaluated the safety, tolerability, and pharmacokinetic and pharmacodynamic properties of the anti-CS1 monoclonal antibody elotuzumab. A standard 3 + 3 design was used to determine maximum tolerated dose; dose-limiting toxicities were assessed during cycle 1. Thirty-five patients with relapsed/refractory multiple myeloma were treated with intravenous elotuzumab at doses ranging from 0.5 to 20 mg/kg every 2 weeks. Patients who achieved at least stable disease after 4 treatments could receive another 4 treatments. No maximum tolerated dose was identified up to the maximum planned dose of 20 mg/kg. The most common adverse events, regardless of attribution, were cough, headache, back pain, fever, and chills. Adverse events were generally mild to moderate in severity, and adverse events attributed to study medication were primarily infusion-related. Plasma elotuzumab levels and terminal half-life increased with dose whereas clearance decreased, suggesting target-mediated clearance. CS1 on bone marrow–derived plasma cells was reliably saturated (≥ 95%) at the 10-mg/kg and 20-mg/kg dose levels. Using the European Group for Bone and Marrow Transplantation myeloma response criteria, 9 patients (26.5%) had stable disease. In summary, elotuzumab was generally well tolerated in this population, justifying further exploration of this agent in combination regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The anti-SLAMF7 antibody elotuzumab has no anti-myeloma activity as monotherapy65, but the addition of this agent to lenalidomide or pomalidomide and dexamethasone improved ORRs, PFS and OS in patients with R/R MM47,66,67.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Tai, Y., Catley, L. P., Mitsiades, C. S., Burger, R., Podar, K., Shringpaure, R., Hideshima, T., Chauhan, D., Hamasaki, M., Ishitsuka, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3630 · Cited by 130
RetractedJemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,432
Brocken, P., van der Heijden, E. H. F. M., Dekhuijzen, P. N. R., Peters-Bax, L., & de Geus‐Oei, L. (2013) · Respiration · doi:10.1159/000347096 · Cited by 4,011
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,309
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Cavo, M., Tacchetti, P., Patriarca, F. F., Petrucci, M. T., Pantani, L., Galli, M., Raimondo, F. D., Crippa, C., Zamagni, E., Palumbo, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61424-9 · Cited by 823
Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
131 I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
Kaminski, M. S., Tuck, M. K., Estes, J. M., Kolstad, A., Ross, C. W., Zasadny, K. R., Regan, D. D., Kison, P. V., Fisher, S., Kroll, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041511 · Cited by 715
Mire‐Sluis, A. R., Barrett, Y. C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E. W., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.06.002 · Cited by 625
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S. M., Draksharapu, A., Shum, B. P., Huseni, M. A., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 558
Self-citationÖsterborg, A., Dyer, M. J. S., Bunjes, D. W., Pangalis, G. A., Bastion, Y., Catovsky, D., & Mellstedt, H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1567 · Cited by 511
Tai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472
Self-citationMultiple myeloma: A review of the epidemiologic literature
Alexander, D. D., Mink, P. J., Adami, H., Cole, P. T., Mandel, J. S., Oken, M. M., & Trichopoulos, D. (2007) · International Journal of Cancer · doi:10.1002/ijc.22718 · Cited by 332
Lonial, S., Vij, R., Harousseau, J., Facon, T. T. F., Moreau, P., Mazumder, A., Kaufman, J. L., Leleu, X. P., Tsao, L. C., Westland, C. E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2649 · Cited by 296
Self-citationMorgan, G. J., Davies, F. E., Gregory, W. M., Russell, N. H., Bell, S., Szubert, A. J., Coy, N. N., Cook, G., Feyler, S., Byrne, J., et al. (2011) · Blood · doi:10.1182/blood-2011-02-338665 · Cited by 197
Zonder, J. A., Crowley, J. J., Hussein, M. A., Bolejack, V., Moore, D. F., Whittenberger, B. F., Abidi, M. H., Durie, B. G. M., & Barlogie, B. (2010) · Blood · doi:10.1182/blood-2010-08-303487 · Cited by 196
Self-citationTuresson, I., Vélez, R., Kristinsson, S. Y., & Landgren, O. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4177 · Cited by 196
van Rhee, F., Szmania, S. M., Dillon, M., van Abbema, A. M., Li, X., Stone, M. K., Garg, T. K., Shi, J., Moreno-Bost, A. M., Yun, R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0483 · Cited by 176
Self-citationWierda, W. G., Padmanabhan, S., Chan, G. W., Gupta, I. V., Lisby, S., Österborg, A., & for the Hx-CD20-406 Study Investigators (2011) · Blood · doi:10.1182/blood-2011-04-348656 · Cited by 159
Tai, Y., Li, X., Tong, X., dos Santos, D. M., Otsuki, T., Catley, L. P., Tournilhac, O., Podar, K., Hideshima, T., Schlossman, R. L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4125 · Cited by 158
Barlogie, B., Attal, M., Crowley, J. J., van Rhee, F., Szymonifka, J. D., Moreau, P., Durie, B. G. M., & Harousseau, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6081 · Cited by 153
Tassone, P., Goldmacher, V. S., Neri, P., Gozzini, A., Shammas, M. A., Whiteman, K. R., Hylander-Gans, L., Carrasco, D. R., Hideshima, T., Shringarpure, R., et al. (2004) · Blood · doi:10.1182/blood-2004-03-0963 · Cited by 124
Anti‐CD20 monoclonal antibody therapy in multiple myeloma
Kapoor, P., Greipp, P. T., Morice, W. G., Rajkumar, S. V., Witzig, T. E., & Greipp, P. R. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07024.x · Cited by 102
Vij, R., Horvath, N., Spencer, A. G., Taylor, K., Vadhan‐Raj, S., Vescio, R. A., Smith, J. W. G., Qian, Y., Yeh, H., & Jun, S. (2009) · American Journal of Hematology · doi:10.1002/ajh.21509 · Cited by 98
Voorhees, P. M., Chen, Q., Small, G. W., Kuhn, D. J., Hunsucker, S. A., Nemeth, J. A., & Orlowski, R. Z. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07647.x · Cited by 89
Monoclonal antibodies in the treatment of multiple myeloma
Richardson, P. G. G., Lonial, S., Jakubowiak, A. J., Harousseau, J., & Anderson, K. C. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08790.x · Cited by 75
Antibody-maytansinoid conjugates for the treatment of myeloma
Lutz, R. J., & Whiteman, K. R. (2009) · mAbs · doi:10.4161/mabs.1.6.10029 · Cited by 62
Zojer, N., Kirchbacher, K., Vesely, M., Hübl, W., & Ludwig, H. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600564803 · Cited by 54
Stevenson, G. T. (2006) · Molecular Medicine · doi:10.2119/2006-00082.stevenson · Cited by 46
Stevenson, G. T. (2007) · PubMed · doi:10.2119/2006–00082.stevenson · Cited by 45
Agura, E. D., Niesvizky, R., Matous, J., Munshi, N. C., Hussein, M. A., Parameswaran, R., Tarantolo, S., Whiting, N. C., Drachman, J. G., & Zonder, J. A. (2009) · Blood · doi:10.1182/blood.v114.22.2870.2870 · Cited by 33
Self-citationRichardson, P. G. G., Moreau, P., Jakubowiak, A. J., Facon, T. T. F., Jagannath, S., Vij, R., Reece, D. E., White, D. J., Raab, M. S., Benboubker, L., et al. (2010) · Blood · doi:10.1182/blood.v116.21.986.986 · Cited by 28
Self-citationLonial, S., Vij, R., Harousseau, J., Facon, T. T. F., Kaufman, J. L., Mazumder, A., Moreau, P., Leleu, X. P., Fry, J., Singhal, A. K., et al. (2009) · Blood · doi:10.1182/blood.v114.22.432.432 · Cited by 19
Self-citationJakubowiak, A. J., Benson, D. M., Bensinger, W., Siegel, D. S. D., Zimmerman, T. M., Mohrbacher, A. M., Richardson, P. G. G., Afar, D., Singhal, A. K., & Anderson, K. C. (2010) · Blood · doi:10.1182/blood.v116.21.3023.3023 · Cited by 11
Self-citationThe effect of elotuzumab on natural killer (NK) cell function against multiple myeloma (MM).
Collins, S. M., Bakan, C. E., Alghothani, Y., Kwon, H., Balasa, B., Starling, G. C., Rice, A. G., & Benson, D. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2572 · Cited by 3
Cited by
Sorted by citations
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 935
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854
Self-citationUsmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705210 · Cited by 407
Metadata
- Authors
- Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K.
- Affiliations
- Wayne State University (US)
- University of Southern California (US)
- Northwestern University (US)
- Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR;
- Fred Hutch Cancer Center (US)
- AbbVie Biotherapeutics (United States) (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-07-19
- Volume
- 120
- Issue
- 3
- Pages
- 552-559
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC4467882
- OpenAlex
- W2000130439
- Cited by
- 342
- References
- 42
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 8 · 2023: 10 · 2022: 16 · 2021: 22 · 2020: 34 · 2019: 25 · 2018: 42 · 2017: 41 · 2016: 48 · 2015: 38 · 2014: 28 · 2013: 21 · 2012: 4
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- National Cancer Institute (P01CA055819)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- elotuzumab, multiple myeloma, CS1, syndecan-1, monoclonal antibodies, dose escalation, maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, pharmacodynamics, safety and tolerability, relapsed/refractory multiple myeloma, stable disease
- MeSH terms
- Aged, Aged, 80 and over, Antineoplastic Agents, Bone Marrow, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Multiple Myeloma, Severity of Illness Index, Treatment Outcome, Lymphocyte Count, Chemokine CXCL10, Antibodies, Neutralizing, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
